Victor Javier Avila-Quintero

Dr. Victor Javier Avila-Quintero

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 November 2021 in Depression and Anxiety
Verified
Journal Article
Closed access
PDF file
SWSamuel T. Wilkinson
Samuel T. Wilkinson
DDDaniel Trujillo Diaz
Daniel Trujillo Diaz
ZRZachary W. Rupp
Zachary W. Rupp
AKAnubhav Kidambi
Anubhav Kidambi
KRKarina L. Ramirez
Karina L. Ramirez
MBMichael H. Bloch
Michael H. Bloch

14 January 2022 in Molecular Psychiatry
Verified
Journal Article
Closed access
PDF file
LFLuis C. Farhat
Luis C. Farhat
JFJosé M. Flores
José M. Flores
EBEmily Behling
Emily Behling
VAVictor Javier Avila-Quintero
Victor Javier Avila-Quintero
ALAdam Lombroso
Adam Lombroso
MBMichael H. Bloch
Michael H. Bloch

2 January 2025 in Regional Anesthesia & Pain Medicine
Verified
Journal Article
Closed access
PDF file
THThomas R Hickey
Thomas R Hickey
GCGabriel P A Costa
Gabriel P A Costa
DODebora Oliveira
Debora Oliveira
APAlexandra Podosek
Alexandra Podosek
AAAudrey Abelleira
Audrey Abelleira
JAJoao P De Aquino
Joao P De Aquino
Background/Importance: Opioids continue to play a key role in managing acute postoperative pain, but their use contributes to adverse outcomes. Buprenorphine may offer effective analgesia with a superior safety profile. Objective: To compare the efficacy and safety of buprenorphine with other opioids for acute postoperative pain management in adults. Evidence review: MEDLINE, Embase, Cochrane Central Register of Controlled Trials, and Web of Science were searched from inception to February 2024. Randomized controlled trials comparing buprenorphine with other opioids for acute postoperative pain management in adults were included. Of 2421 records identified, 58 studies met inclusion criteria. Two reviewers independently extracted data and assessed risk of bias. Random-effects meta-analysis was performed using Stata/BE V.18. The primary outcome was pain intensity. Secondary outcomes included rescue analgesia use, duration of analgesia, and adverse effects. Findings: Analysis of 41 comparisons (2587 participants) showed buprenorphine significantly reduced pain intensity compared with all other opioids (Hedges’s g=−0.36, 95% CI=−0.59 to −0.14, p<0.001, 95% prediction interval (PI)=−1.70 to 0.97). This effect persisted when compared with full agonist opioid (FAO) alone (standardized mean difference −0.34, 95% CI=−0.59 to −0.10, p<0.001, 95% PI=-1.76 to 1.07). Patients receiving buprenorphine were less likely to require rescue analgesia (OR=0.40, 95% CI=0.26 to 0.63, p<0.001, 95% PI=0.12 to 1.36). Mean duration of analgesia was 8.5 hours (SD 1.84). There were no significant differences in other adverse effects including nausea and respiratory depression. Inconsistency was significant for pain intensity (I 2 =86.28%, 95% CI=81.55% to 88.99%) and moderate for rescue analgesia (I 2 =38.93%, 95% CI=1.44% to 64.37%). Risk of bias was low in 19 studies, with some concerns in 37 studies, and high in two studies. Conclusions: Buprenorphine demonstrated superior efficacy in managing acute postoperative pain compared with FAOs, with a favorable safety profile and longer duration of action. These findings support the use of buprenorphine as a first-line opioid analgesic for acute postoperative pain management requiring opioid analgesia, potentially reducing opioid-related harm in the postoperative period. PROSPERO registration number: CRD42023447715.

1 March 2024 in Journal of Child and Adolescent Psychopharmacology
Verified
Journal Article
Closed access
ALAlice Lineham
Alice Lineham
VAVictor Javier Avila-Quintero
Victor Javier Avila-Quintero
MBMichael H. Bloch
Michael H. Bloch
JDJennifer Dwyer
Jennifer Dwyer
Objective: Ketamine has proved effective as a rapid-acting antidepressant agent, but treatment is not effective for everyone (approximately a quarter to a half of patients). Some adult studies have begun to investigate predictors of ketamine's antidepressant response, but no studies have examined this in adolescents with depression. Methods: We conducted a secondary data analysis of adolescents who participated in a randomized, single-dose, midazolam-controlled crossover trial of ketamine for adolescents with treatment-resistant depression. We examined the relationship between 19 exploratory demographic and clinical variables and depression symptom improvement (using the Montgomery-Åsberg Depression Rating Scale [MADRS]) at 1 and 7 days postinfusion. Results: Subjects who had fewer medication trials of both antidepressant medications and augmentation treatments were more likely to experience depression symptom improvement with ketamine. Subjects with shorter duration of their current depressive episode were more likely to experience depression symptom improvement with ketamine. Subjects currently being treated with selective serotonin reuptake inhibitor medications, and not being treated with serotonin–norepinephrine reuptake inhibitor medications, also experienced greater symptom improvement with ketamine. When receiving the midazolam control, less severe depressive symptoms, as measured by the Children's Depression Rating Scale (CDRS) (but not MADRS), and a comorbid attention-deficit/hyperactivity disorder diagnosis were associated with increased response. Conclusions: Findings should be viewed as preliminary and exploratory given the small sample size and multiple secondary analyses. Identifying meaningful predictors of ketamine response is important to inform future therapeutic use of this compound, however, considerably more research is warranted before such clinical guidance is established. The trial was registered in clinicaltrials.gov with the identifier NCT02579928.

2 January 2023 in Journal of Intensive Care Medicine
Verified
Journal Article
Closed access
ARAnirudh Rao
Anirudh Rao
MAMuhtadi H. Alnababteh
Muhtadi H. Alnababteh
VAVictor Javier Avila-Quintero
Victor Javier Avila-Quintero
JFJose M. Flores
Jose M. Flores
NLNina E. Laing
Nina E. Laing
AZAkram M. Zaaqoq
Akram M. Zaaqoq
Background: Members of racial and ethnic minority groups have been disproportionately impacted by coronavirus-2019 (COVID-19). The objective of the study is to describe associations between race and ethnicity on clinical outcomes such as need for mechanical ventilation and mortality. Methods: Retrospective cohort study of patients with severe COVID-19 infection admitted within a large, not-for-profit healthcare system in the mid-Atlantic region between March and July, 2020. Patient demographic data and clinical outcomes were abstracted from the electronic health record. Logistic regressions were performed to estimate associations between race and ethnicity and the clinical outcomes. Results: The study population (N = 2931) was stratified into 1 of 3 subgroups: non-Hispanic White (n = 466), non-Hispanic Black (n = 1611), and Hispanic (n = 654). The average age of White, Black, and Hispanic patients was 69 ± 17.06, 64 ± 15.9, and 50 ± 15.53 years old, respectively ( P < .001). Compared to White patients, Black and Hispanic patients were at increased odds of needing mechanical ventilation due to COVID-19 pneumonia (odds ratio [OR] Black = 1.35, 95% confidence interval [CI] = 1.04 to 1.75, P < .05; OR Hispanic = 1.43, 95% CI = 1.06 to 1.93, P < .05). When compared to White patients, Hispanic patients were at decreased odds of death (OR = 0.45, 95% CI = 0.32 to 0.63, P < .001). However, when adjusting for age, there were no statistically significant differences in the odds of death between these groups (adjusted OR [aOR] Black = 1.05, 95% CI = 0.80 to 1.38, P = .71; aOR Hispanic = 1.10, 95% CI = 0.76 to 1.60, P = .62). Conclusion: Our analysis demonstrated that Hispanic patients were more likely require mechanical ventilation but had lower mortality when compared to White patients, with lower average age likely mediating this association. These findings emphasize the importance of outreach efforts to communities of color to increase prevention measures and vaccination uptake to reduce infection with COVID-19.

9 January 2025 in Regional Anesthesia & Pain Medicine
Verified
Journal Article
Open access
PDF file
THThomas R Hickey
Thomas R Hickey
GCGabriel P A Costa
Gabriel P A Costa
VAVictor Javier Avila-Quintero
Victor Javier Avila-Quintero
JAJoao P De Aquino
Joao P De Aquino
Opioids continue to play a role in postoperative pain management and continue to result in predictable harm to patients including persistent use and overdose.1 Buprenorphine, a partial agonist opioid, has an almost 60-year track record of efficacy in acute pain management. However, in contemporary practice, it is rarely used for this purpose and is better known as an essential medicine for opioid use disorder. In this systematic review and meta-analysis of randomized controlled trials, the authors aimed to broaden the understanding of buprenorphine’s efficacy versus opioids as a class in the treatment of acute postoperative pain in adults. Inclusion criteria were met for 58 studies.